S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.86 (+1.79%)
AAPL   143.23 (+4.10%)
MSFT   260.96 (+3.33%)
FB   196.36 (+1.46%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,153.50 (+0.08%)
TSLA   675.13 (+1.69%)
NVDA   169.57 (+1.58%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.39 (+2.02%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.76 (+1.76%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.66 (-3.08%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.86 (+1.79%)
AAPL   143.23 (+4.10%)
MSFT   260.96 (+3.33%)
FB   196.36 (+1.46%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,153.50 (+0.08%)
TSLA   675.13 (+1.69%)
NVDA   169.57 (+1.58%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.39 (+2.02%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.76 (+1.76%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.66 (-3.08%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.86 (+1.79%)
AAPL   143.23 (+4.10%)
MSFT   260.96 (+3.33%)
FB   196.36 (+1.46%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,153.50 (+0.08%)
TSLA   675.13 (+1.69%)
NVDA   169.57 (+1.58%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.39 (+2.02%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.76 (+1.76%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.66 (-3.08%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.86 (+1.79%)
AAPL   143.23 (+4.10%)
MSFT   260.96 (+3.33%)
FB   196.36 (+1.46%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,153.50 (+0.08%)
TSLA   675.13 (+1.69%)
NVDA   169.57 (+1.58%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.39 (+2.02%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.76 (+1.76%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.66 (-3.08%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
NASDAQ:LMNL

Liminal BioSciences News Headlines

$0.53
-0.06 (-10.02%)
(As of 05/23/2022 02:35 PM ET)
Add
Compare
Today's Range
$0.53
$0.54
50-Day Range
$0.52
$1.04
52-Week Range
$0.37
$6.30
Volume
71 shs
Average Volume
61,523 shs
Market Capitalization
$16.48 million
P/E Ratio
0.67
Dividend Yield
N/A
Beta
1.57
Get Liminal BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for LMNL and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Liminal BioSciences Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

LMNL
News Sentiment

0.00

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

LMNL Articles
This Week

2

0

LMNL Articles
Average Week



Liminal BioSciences (NASDAQ:LMNL) News Headlines Today

SourceHeadline
finanznachrichten.de logoLiminal BioSciences Inc.: Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras
finanznachrichten.de - May 23 at 8:10 AM
finance.yahoo.com logoLiminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras
finance.yahoo.com - May 23 at 8:10 AM
seekingalpha.com logoLiminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 4:59 PM
finance.yahoo.com logoLiminal BioSciences Inc. (LMNL) Could Find Support Soon, Here's Why You Should Buy the Stock Now
finance.yahoo.com - May 13 at 4:59 PM
MarketBeat logoLiminal BioSciences (NASDAQ:LMNL) Lifted to "Buy" at Zacks Investment Research
americanbankingnews.com - May 12 at 1:52 AM
seekingalpha.com logoLiminal BioSciences Inc. 2022 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 11 at 3:30 PM
finanznachrichten.de logoLiminal BioSciences Inc.: Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights
finanznachrichten.de - May 10 at 7:50 PM
seekingalpha.com logoLiminal BioSciences reports Q1 results
seekingalpha.com - May 10 at 7:50 PM
finance.yahoo.com logoLiminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights
finance.yahoo.com - May 10 at 7:50 PM
finance.yahoo.com logoLiminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022
finance.yahoo.com - May 9 at 6:36 PM
finanznachrichten.de logoLiminal BioSciences Inc.: Liminal Biosciences to Present at Upcoming Investor Conferences
finanznachrichten.de - May 9 at 1:36 PM
finance.yahoo.com logoLiminal Biosciences to Present at Upcoming Investor Conferences
finance.yahoo.com - May 9 at 8:35 AM
MarketBeat logoLiminal BioSciences (NASDAQ:LMNL) Cut to Hold at Zacks Investment Research
americanbankingnews.com - May 5 at 3:02 AM
MarketBeat logoContrasting Liminal BioSciences (NASDAQ:LMNL) & Allakos (NASDAQ:ALLK)
americanbankingnews.com - May 3 at 1:48 AM
seekingalpha.com logoLiminal BioSciences reports FY results
seekingalpha.com - March 18 at 7:40 AM
finanznachrichten.de logoLiminal BioSciences Inc.: Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results
finanznachrichten.de - March 17 at 9:39 PM
seekingalpha.com logoLiminal BioSciences plans additional Phase 1 trial for lead asset next quarter
seekingalpha.com - March 14 at 1:10 PM
finanznachrichten.de logoLiminal BioSciences Inc.: Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras
finanznachrichten.de - March 14 at 8:10 AM
finanznachrichten.de logoLiminal BioSciences Inc.: Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
finanznachrichten.de - March 7 at 10:55 PM
seekingalpha.com logoLiminal BioSciences gets Nasdaq notice on minimum bid price deficiency
seekingalpha.com - March 7 at 10:55 PM
finance.yahoo.com logoLiminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
finance.yahoo.com - March 7 at 10:55 PM
finanznachrichten.de logoLiminal BioSciences Inc.: Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP
finanznachrichten.de - February 16 at 11:33 AM
finance.yahoo.com logoLiminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP
finance.yahoo.com - February 16 at 11:33 AM
nasdaq.com logoLiminal BioSciences Inc. Common Shares (LMNL)
nasdaq.com - February 7 at 9:59 PM
markets.businessinsider.com logoOcugen To Buy Liminal's Dormant Vaccine Manufacturing Plant In Canada
markets.businessinsider.com - January 27 at 3:07 PM
finance.yahoo.com logoLiminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022
finance.yahoo.com - January 20 at 11:50 AM
finanznachrichten.de logoLiminal BioSciences Inc.: Liminal BioSciences Announces Strategic Priorities For 2022
finanznachrichten.de - January 19 at 6:41 PM
seekingalpha.com logoLiminal Biosciences provides update on research programs
seekingalpha.com - January 19 at 6:41 PM
finance.yahoo.com logoLiminal BioSciences Announces Strategic Priorities For 2022
finance.yahoo.com - January 19 at 6:41 PM
finanznachrichten.de logoLiminal BioSciences Inc.: Liminal BioSciences Reports Third Quarter 2021 Financial Results
finanznachrichten.de - November 15 at 8:36 PM
finance.yahoo.com logoLiminal BioSciences Reports Third Quarter 2021 Financial Results
finance.yahoo.com - November 15 at 8:36 PM
finance.yahoo.com logoLiminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
finance.yahoo.com - November 4 at 9:19 PM
finanznachrichten.de logoLiminal BioSciences Inc.: Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business
finanznachrichten.de - October 15 at 7:49 PM
finance.yahoo.com logoLiminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business
finance.yahoo.com - October 15 at 7:49 PM
finanznachrichten.de logoLiminal BioSciences Inc.: Liminal BioSciences Announces Closing of Sale of Priority Review Voucher
finanznachrichten.de - September 29 at 12:24 AM
finance.yahoo.com logoLiminal BioSciences Announces Closing of Sale of Priority Review Voucher
finance.yahoo.com - September 29 at 12:24 AM
finance.yahoo.com logoAfter Plunging 34.5% in 4 Weeks, Here's Why the Trend Might Reverse for Liminal BioSciences Inc. (LMNL)
finance.yahoo.com - August 23 at 5:36 PM
seekingalpha.com logoLiminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q2 2021 Results - Earnings Call Transcript
seekingalpha.com - August 18 at 5:50 AM
seekingalpha.com logoLiminal BioSciences Inc. 2021 Q2 - Results - Earnings Call Presentation
seekingalpha.com - August 17 at 8:00 PM
nasdaq.com logoLiminal BioSciences Inc. (LMNL) Reports Q2 Loss, Misses Revenue Estimates
nasdaq.com - August 17 at 1:41 AM
finance.yahoo.com logoLiminal BioSciences Reports Second Quarter 2021 Financial Results
finance.yahoo.com - August 16 at 8:40 PM
nasdaq.com logoLiminal Biosciences Inc Shares Close the Day 17.8% Lower - Daily Wrap
nasdaq.com - August 11 at 1:01 AM
nasdaq.com logoLiminal BioSciences To Sell Rare Pediatric Disease Priority Review Voucher For $105 Mln
nasdaq.com - August 9 at 8:14 AM
finance.yahoo.com logoLiminal BioSciences Announces Sale of Priority Review Voucher for USD105M
finance.yahoo.com - August 9 at 8:14 AM
finance.yahoo.com logoLiminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - August 2 at 6:21 PM
baystreet.ca logoLiminal Cuts Loose on FDA Nod
baystreet.ca - June 7 at 1:44 PM
finance.yahoo.com logoLiminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)
finance.yahoo.com - June 4 at 5:40 PM
finance.yahoo.com logoLiminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras
finance.yahoo.com - May 28 at 7:50 PM
finance.yahoo.com logoLiminal Biosciences Completes Plasma Centers Sale; Stock Jumps 4.65%
finance.yahoo.com - May 24 at 2:14 PM
finance.yahoo.com logoLiminal BioSciences Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 17 at 6:32 PM
Get Liminal BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for LMNL and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.